Ovitrelle Injection
Choriogonadotropin Alfa
250mg
INDUSTRIA PHARMACEUTICA SERONO S.p.A.
| Pack size | 0.5ml Pre-filled Syringe |
|---|---|
| Dispensing mode | POM |
| Source | ITALY |
| Agent | ARABIAN ETHICALS CO. |
| Retail Price | 246.50 AED |
Available as:
Indications
Ovitrelle Injection is used for:
Anovulatory infertility, Adjunct to IVF procedures and other assisted conception techniques
Adult Dose
Induction of Ovulation & Pregnancy
250 mcg SC one day following last dose of follicle stimulating agent; use only after adequate follicular development has been determined; hold treatment if there is excessive ovarian response
5,000-10,000 units 1 day following last dose of menotropins
Induction of Spermatogenesis
Hypogonadotropic and hypogonadism in males: 1000-2000 units 2-3 times/week (may require 2-3 months of therapy); if needed, add follitropin alfa or menopausal gonadotropin to induce spermatogenesis; continue hCG therapy at dose required to maintain testosterone levels
Child Dose
Prepubertal Cryptorchidism Not Caused By Anatomical Obstruction
May institute therapy between ages of 4 and 9
4,000 units IM 3 times/week for 3 weeks
5,000 units IM every second day for 4 injections
15 injections of 500 to 1,000 units IM over a period of 6 weeks
500 units IM 3 times/week for 4-6 weeks; if course of treatment not successful, begin another 1 month later, giving 1,000 units/injection
Male Hypogonadotropic Hypogonadism
500-1,000 units IM 3 times/week for 3 weeks, followed by same dose twice/week for 3 weeks
4,000 units IM 3 times/week for 6-9 months; following that dosage may be reduced to 2,000 units 3 times/week for an additional 3 months
Renal Dose
Administration
Contra Indications
Ovarian enlargement or cyst (unless caused by polycystic ovarian disease); ectopic pregnancy in previous 3 months; active thromboembolic disorders; hypothalamus, pituitary, ovarian, uterine or mammary malignancy; gynaecological haemorrhage of unknown etiology; primary ovarian failure; sexual organ malformations and fibroid uterine tumors incompatible with pregnancy; postmenopausal women. Uncontrolled thyroid or adrenal dysfunction. Pregnancy and lactation.
Precautions
Asthma, epilepsy, migraine, CV disorders, renal disorders; infertility caused by hyperprolactinaemia, pituitary or hypothalamic tumors; clinically significant systemic diseases where pregnancy could exacerbate the condition. Monitor carefully estradiol levels and ovarian response based on ultrasound prior to and during stimulation therapy. Multiple pregnancy.
Lactation: Not known if distributed in breast milk; use caution
Pregnancy-Lactation
Pregnancy Category: X
Lactation: Not known if distributed in breast milk; use caution
Interactions
Adverse Effects
Side effects of Choriogonadotropin Alfa :
1-10%
Ovarian cyst (3%), Ovarian hyperstimulation (2-3%), Abdominal pain (3-4%), Nausea (3%), Vomiting (3%), Injection site inflammation (<2%)
<1%
Breast pain, Cervical lesion, Cough, Albuminuria, Back pain, Breast pain, Cardiac arrhythmia, Dizziness, Emotional lability, Genial herpes, Hyperglycemia, Pruritus, Urinary tract infection, Vaginal hemorrhage, Vaginitis
Frequency Not Defined
Headache, Irritability, Depression, Edema, Restlessness, Gynecomastia, Precocious puberty, Fatigue, Arterial thrombus, Ovarian hyperstimulation syndrome
Mechanism of Action
Choriogonadotropin alfa is a recombinant form of chorionic gonadotrophin. Its effects mimic those of leuteinizing hormone, which triggers ovulation and formation of the corpus luteum in women and stimulates the production of testosterone by the testes in men.
Note
Ovitrelle 250mg Injection manufactured by INDUSTRIA PHARMACEUTICA SERONO S.p.A.. Its generic name is Choriogonadotropin Alfa. Ovitrelle is availble in United Arab Emirates.
Farmaco UAE drug index information on Ovitrelle Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.